What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “LEAF-4L6715: Administration at a dose of 200mg , for up to 10 days every 12 hours for the first 2 days, followed by once-a-day dosing for the next 8 days (days 3 through 10).”In the company’s words, NCT06640777 on ClinicalTrials.gov
- Tested for
- Acute Respiratory Distress Syndrome
- Main trialPhase 3
- “Acute Respiratory Distress Syndrome (ARDS) is a serious condition where people in hospital care suddenly have trouble breathing because of infection, pneumonia, COVID-19 or other disease. People with ARDS may have to be put in an intensive care unit (ICU) and on a ventilator to help them breathe. This trial is to try to find out if injecting a product called LEAF-4L6715 makes the treatment better or worse than what is normally given. LEAF-4L6715 is a product that contains tiny bubbles to slowly release a substance named transcrocetin which scientific studies show may increase oxygen flow and…”In the company’s words, NCT06640777 on ClinicalTrials.gov
- Other names
- Liposomal transcrocetin
Other drugs for Acute Respiratory Distress Syndrome
- APC-0101Aerogen Pharma Limited · Phase 3
- TozorakimabAstraZeneca · Phase 3
- ExoFloDirect Biologics, LLC · Phase 3
- Aerosolized CalfactantONY · Phase 3
- STSA-1002Staidson (Beijing) Biopharmaceuticals Co., Ltd · Phase 3
- SecretomePT. Prodia Stem Cell Indonesia · Phase 1/2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 9 Nov 2026 | Efficacy and Safety of LEAF-4L6715 for Acute Respiratory Distress Syndrome |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026